Original ContributionPhase II Trial of Doxorubicin/Docetaxel/Cyclophosphamide for Locally Advanced and Metastatic Breast Cancer: Results from NSABP Trial BP-58
References (31)
- et al.
A phase II trial with docetaxel (Taxotere) in second line treatment with chemotherapy for advanced breast cancer. A study of the EORTC Early Clinical Trials Group
Ann Oncol
(1994) - et al.
Combined doxorubicin and paclitaxel in advanced breast cancer: effective and cardiotoxic
Ann Oncol
(1996) - et al.
Dose-finding study of docetaxel and doxorubicin in first-line treatment of patients with metastatic breast cancer
Ann Oncol
(1999) - et al.
Comparative studies of taxol and taxotere on tumor growth and lymphocyte functions
Gynecol Oncol
(1994) - et al.
Preclinical evaluation of the cardiotoxicity of taxane-anthracycline combinations using the model of isolated perfused rat heart
Toxicol Appl Pharmacol
(2000) - et al.
Pharmacokinetic profiles of doxorubicin in combination with taxanes
Semin Oncol
(2001) - et al.
Paclitaxel in metastatic breast cancer: a trial of two doses by a 3-hour infusion in patients with disease recurrence after prior therapy with anthracyclines
J Natl Cancer Inst
(1995) - et al.
Paclitaxel as second and subsequent chemotherapy for metastatic breast cancer: activity independent of prior anthracycline response
J Clin Oncol
(1995) - et al.
Paclitaxel in doxorubicin-refractory or mitoxantrone-refractory breast cancer: a phase I/II trial of 96-hour infusion
J Clin Oncol
(1994) - et al.
Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer
J Clin Oncol
(1995)
Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer
J Clin Oncol
(1995)
Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. The 303 Study Group
J Clin Oncol
(1999)
Improved disease-free (DFS) and overall survival (OS) from the addition of sequential paclitaxel (T) but not from the escalation of doxorubicin (A) dose level in the adjuvant chemotherapy of patients (PTS) with node-positive primary breast cancer (BC)
Proc Am Soc Clin Oncol
(1998)
Cited by (20)
MYC Amplification as a Predictive Factor of Complete Pathologic Response to Docetaxel-based Neoadjuvant Chemotherapy for Breast Cancer
2017, Clinical Breast CancerCitation Excerpt :The taxanes have substantial activity against breast cancer, even after failed treatment with anthracyclines.7 However, the treatment with this regimen presents several adverse effects, including nausea, vomiting, low white blood cell counts, cardiotoxicity, fever, diarrhea, and peripheral neuropathy.8,9 Currently, there are no clinically useful predictive markers to identify patients who are likely to respond to taxanes.10
Chemotherapy Protocols and Infusion Sequence: Schedule Consideration in Cancer Treatment
2022, Chemotherapy Protocols and Infusion Sequence: Schedule Consideration in Cancer Treatment
Copyright © 2002 Elsevier Inc. All rights reserved.